Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (31-40 of 515) with videos related to

Pageof 52
Sort By:
Leukemia & Lymphoma|July 26, 2021
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myelomaSaurabh Zanwar, Shaji Kumar
Leukemia & Lymphoma|January 12, 2018
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promiseVijay Ramakrishnan, Shaji Kumar
Rare Cancers and Therapy|May 17, 2016
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesJeremy T Larsen, Shaji Kumar
Expert Review of Anticancer Therapy|October 14, 2005
Thalidomide and dexamethasone: therapy for multiple myelomaShaji Kumar, S Vincent Rajkumar
The New England Journal of Medicine|December 30, 2025
Monoclonal Gammopathy of Undetermined Significance. ReplyS Vincent Rajkumar, Shaji Kumar
Blood Cancer Journal|September 29, 2020
Multiple myeloma current treatment algorithmsS Vincent Rajkumar, Shaji Kumar
Leukemia & Lymphoma|February 14, 2024
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use themMatthew James Rees, Shaji Kumar
American Journal of Hematology|April 13, 2024
High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapyMatthew J Rees, Shaji Kumar
The American Journal of Gastroenterology|June 24, 2003
Acute superior mesenteric venous thrombosis: one disease or two?Shaji Kumar, Patrick S Kamath
Blood|September 10, 2008
Many facets of bortezomib resistance/susceptibilityShaji Kumar, S Vincent Rajkumar
Pageof 52

Showing results (31-40 of 515) with videos related to

Sort By:
Pageof 52
Leukemia & Lymphoma|July 26, 2021
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myelomaSaurabh Zanwar, Shaji Kumar
Leukemia & Lymphoma|January 12, 2018
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promiseVijay Ramakrishnan, Shaji Kumar
Rare Cancers and Therapy|May 17, 2016
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesJeremy T Larsen, Shaji Kumar
Expert Review of Anticancer Therapy|October 14, 2005
Thalidomide and dexamethasone: therapy for multiple myelomaShaji Kumar, S Vincent Rajkumar
The New England Journal of Medicine|December 30, 2025
Monoclonal Gammopathy of Undetermined Significance. ReplyS Vincent Rajkumar, Shaji Kumar
Blood Cancer Journal|September 29, 2020
Multiple myeloma current treatment algorithmsS Vincent Rajkumar, Shaji Kumar
Leukemia & Lymphoma|February 14, 2024
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use themMatthew James Rees, Shaji Kumar
American Journal of Hematology|April 13, 2024
High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapyMatthew J Rees, Shaji Kumar
The American Journal of Gastroenterology|June 24, 2003
Acute superior mesenteric venous thrombosis: one disease or two?Shaji Kumar, Patrick S Kamath
Blood|September 10, 2008
Many facets of bortezomib resistance/susceptibilityShaji Kumar, S Vincent Rajkumar
Pageof 52